Global Cell Based Assays Market

1 INTRODUCTION OF GLOBAL CELL BASED ASSAYS MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CELL BASED ASSAYS MARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL CELL BASED ASSAYS MARKET, BY APPLICATION
5.1 Overview
5.2 Drug Discovery
5.3 Basic Research
5.4 Adme Studies
5.5 Predictive Toxicology
5.6 Others

6 GLOBAL CELL BASED ASSAYS MARKET, BY END USER
6.1 Overview
6.2 Pharmaceutical & Biotechnology Companies
6.3 Academic & Government Institutions
6.4 Contract Research Organizations
6.5 Others

7 GLOBAL CELL BASED ASSAYS MARKET, BY PRODUCTS AND SERVICES
7.1 Overview
7.2 Consumables
7.2.1 Reagents
7.2.2 Assay Kits
7.2.2.1 Reporter Gene Assays
7.2.2.2 Cell Growth Assays
7.2.2.3 Second Messenger Assays
7.2.2.4 Cell Death Assays
7.2.2.5 Other Assays
7.2.3 Microplates
7.2.4 Cell Lines
7.2.4.1 Immortalized Cell Lines
7.2.4.2 Primary Cell Lines
7.2.4.3 Stem Cell Lines
7.2.5 Probes and Labels
7.2.6 Others
7.3 Instruments
7.4 Services
7.5 Software

8 GLOBAL CELL BASED ASSAYS MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL CELL BASED ASSAYS MARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Becton, Dickinson and Company
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Danaher Corporation
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Thermo Fisher Scientific Inc.
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 General Electric Company
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Merck KGaA
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Perkinelmer, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Charles River Laboratories, Inc.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Lonza Group Ltd.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Cell Signaling Technology, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Promega Corporation
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Sydney Essential Oil Co. (SEOC)
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments
10.12 The Lebermuth Company
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

10.13 Cisbio Bioassays
10.13.1 Overview
10.13.2 Financial Performance
10.13.3 Product Outlook
10.13.4 Key Developments

10.14 Cell Biolabs, Inc.
10.14.1 Overview
10.14.2 Financial Performance
10.14.3 Product Outlook
10.14.4 Key Developments

10.15 Discoverx Corporation
10.15.1 Overview
10.15.2 Financial Performance
10.15.3 Product Outlook
10.15.4 Key Developments

11 Appendix
11.1 Related Reports